SEC filing flags restatement and internal control weakness
Pelthos Therapeutics Inc. (PTHS.A) said its financial statements should no longer be relied upon for the quarter ended March 31, according to an SEC filing.
The company said it will restate financial statements for the affected period.
Pelthos said the restatement will not impact liquidity or cash position for the quarter ended March 31, 2026, according to the filing.
The company also identified a material weakness in internal control as of March 31, 2026, the SEC filing said.
PTHS•
